Evercore ISI Group has initiated coverage on Penumbra Inc (PEN) with an Outperform rating as of September 1, 2025. This marks the firm's first assessment of the company's investment potential, grounded in their analysis of the business, industry dynamics, and growth prospects.
Penumbra, headquartered in Alameda, California, specializes in innovative medical products aimed at thrombectomy. The company has built a broad portfolio that includes computer-assisted vacuum thrombectomy (CAVT) devices designed to remove blood clots from various parts of the body. With a workforce of approximately 4,500 employees, Penumbra focuses on improving clinical outcomes for conditions such as Pulmonary Embolism, Deep Vein Thrombosis, and Ischemic Stroke.
Currently, Penumbra holds a market capitalization of $11.0 billion and a trailing twelve-month price-to-earnings ratio of 66.86, reflecting its growth-oriented business model. The company has shown strong recent earnings performance, with Q3 2025 EPS reported at $0.97, exceeding estimates by 4.2%. Upcoming earnings are anticipated on July 27, 2026, with an estimated EPS of $1.21 and revenue of $391.3 million.
Such ratings and price targets from analysts serve as professional opinions derived from extensive research and financial modeling. They provide insights but are based on assumptions that may not always materialize. Investors should consider a range of factors, including company fundamentals and market trends, when evaluating potential investments.
As of November 1, 2025, the analyst consensus for Penumbra indicates a Buy rating, with 8 Strong Buy, 12 Buy, and 4 Hold recommendations, reflecting a generally positive outlook among analysts. The recent initiation of coverage by Evercore ISI underscores the growing attention on Penumbra's innovative approach in the healthcare sector.